Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.

Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.

Abstract: Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred embodiment subject matter of the invention is an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of kidney dysfunction or kidney failure or liver dysfunction or liver failure.

Abstract: Disclosed is CD31shed for use as a molecular imaging target in the molecular imaging of an inflammatory condition. Administering the radiolabeled peptide P8RI as CD31shed ligand in different rat models of inflammation indeed showed that CD31shed is present on activated cells in a quantity allowing a detectable signal, whereas the noise signal corresponding to CD31shed present on activated circulating cells and on other organs or cells not involved in inflammation was little. Also disclosed is a labeled CD31shed ligand and the use thereof as a molecular imaging agent in the molecular imaging of an inflammatory condition. The molecular imaging of inflammatory sites particularly allows determining whether a subject suffers from or is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.

Abstract: The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.

Abstract: The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.

Abstract: There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD-L1, PD-L1-binding fragments that can be manufactured at higher yields.

Abstract: The present invention provides multispecific Fab fusion proteins (MSFP) that specifically bind to CD3 and EpCAM. The present invention further provides uses of the MSFPs for the preparation of pharmaceutical compositions, methods of treating cancer, and kits comprising the MSFPs. Also provided are anti-EpCAM antibodies or antigen-binding fragments thereof.

Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

Abstract: The present invention encompasses the discovery that the likelihood of a favorable response to cancer immunotherapy for a wide range of different cancers can be predicted through definition of a tumor mutational load threshold for the tumor (and/or the relevant immunotherapy).

Abstract: Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anto-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo-non invasive imaging and/or assessments.

Abstract: The present disclosure provides binding proteins, such as antibodies, that bind to a GDNF Family Receptor Alpha Like (GFRAL) protein, including human GFRAL protein, and methods of their use.

Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.

Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.

Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-? and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.

Abstract: The present invention relates to humanized antibodies that specifically bind to human transferrin receptor and their use in treating cancer and inflammatory disorders.

Abstract: The present application relates, in part, to agents that bind CD20 and their use as therapeutic agents. The present application further relates to pharmaceutical compositions comprising the CD20 binding agents and their use in the treatment of various diseases.

Abstract: The present invention relates to modified antibodies. In particular, the present invention relates to recombinant monoclonal antibodies or fragments, including chimeric, primatized or humanized antibodies or fragments, having reduced effector function and altered ability to mediate cell signaling activity by a target antigen. In addition, the present invention relates to nucleic acid molecules encoding such antibodies, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the antibodies of the invention, and to methods of using these antibodies in treatment of disease.

Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.

Abstract: A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.

Abstract: The present invention provides, among other things, methods and compositions for diagnosing and/or treating cancer by targeting CCR8. In particular, the present invention provides technologies for depleting Treg cells, and particularly tumor-infiltrating Treg cells.

Abstract: The present invention provides an antibody which binds to human p53 tumour suppressor protein residues 65-73 (human p5365-73), as shown in SEQ ID NO: 1, when presented by the MHC class I protein Human Leukocyte Antigen-A*0201 (HLA-A*0201).

Abstract: This application provides anti-PCSK9˜GLP-1 fusions and methods for use.

Abstract: In a prior art reactor set up dense aggregates of microorganisms are formed, typically in or embedded in an extra cellular matrix. Such may relate to granules, to sphere like entities having a higher viscosity than water, globules, a biofilm, etc. The dense aggregates comprise extracellular polymeric substances, or biopolymers, in particular linear polysaccharides, The present invention is in the field of extraction a biopolymer from a granular sludge, a fibrous biopolymer obtained by said process, in particular alginate or bacterial alginate, and a use of said biopolymer.

Abstract: According to a method for the manufacture of a prophylactic article, especially of a glove, from a (carboxylated) diene rubber, at least one layer of a (carboxylated) diene latex is applied on a former and the (carboxylated) diene latex is cross-linked with a cross-linking agent, wherein a mercapto-functional siloxane polymer is used as cross-linking agent.

Abstract: The present invention provides a gel formed by a host-guest interaction and having self-healing and shape-memory properties, and a process for producing the gel. A monomer containing a host group, a monomer containing a guest group, and an acrylic type monomer were dissolved in an aqueous solvent, and these monomers were subsequently copolymerized to produce a gel obtained from these monomers.

Abstract: An alkyl metalloxane compound and a method of producing the same are provided. The alkyl metalloxane compound includes one or more alkyl aluminoxane structural units, and one or more alkyl galloxane structural units per molecule. The method comprises reacting trialkyl gallium, trialkyl aluminum, and water.

Abstract: An oxygen permeable polymer has the following formula: wherein RS is a non-sulfonyl halide portion of a sulfonyl halide monomer or polymer; XP is —NH or —NHCO; A is an optionally substituted alkyl; L is 0, 1 or 2; m is 2 or 3; Z is H or CH3; and n is 5?m. The polymer can be used in air separation devices, air concentrators, and in electrodes for electrochemical devices.

Abstract: A synthetic polymer film is a synthetic polymer film whose surface has a plurality of raised or recessed portions. The synthetic polymer film has a crosslink structure, and the crosslink structure does not contain any nitrogen element that is a constituent of a urethane bond. The synthetic polymer film contains an organic carboxylic acid, and an amount of water required for dissolving 1 g of the organic carboxylic acid is equal to or greater than 10 mL and less than 10000 mL. At the lapse of 5 minutes since placing a 200 ?L drop of water on the surface of the synthetic polymer film, a pH of an aqueous solution is not more than 5, and an area equivalent circle diameter of the aqueous solution is not less than 20 mm. A synthetic polymer film whose surface has a microbicidal activity can be produced using a photocurable resin composition which contains an organic carboxylic acid or a photoacid generator which generates the organic carboxylic acid.

Abstract: Disclosed are saturated cyclic monopolymers derived from hexyne, octyne, nonyne, pentadecyne and saturated cyclic copolymers derived from acetylene and a second alkyne monomer that is hexyne, octyne, nonyne, or pentadecyne.

Abstract: This invention generally relates to a method for modulating interfacial wettability of a noncovalent nanoscopic monolayer or thin film. Particularly, this invention relates to a method for modulating interfacial wettability of a two-dimensional (2D) material using a molecular layer prepared from a polymerizable amphiphilic monomer having a hydrophilic head and a hydrophobic tail, wherein enhanced or decreased wettability of said 2D material is achieved by proper allocating the position of polymerizable group relative to the hydrophilic head and the hydrophobic tail.

Abstract: Methods for producing polyolefin polymers may use a predictive melt index regression to estimate the melt index of the polyolefin during production based on the composition of the gas phase and, optionally, the concentration of catalyst in the reactor or reactor operating conditions. Such predictive melt index regression may include multiple terms to account for concentration of ICA in the reactor, optionally concentration of hydrogen in the reactor, optionally concentration of comonomer in the reactor, optionally the catalyst composition, and optionally reactor operating conditions. One or more terms may independently be represented by a smoothing function that incorporates a time constant.

Abstract: The metallocene compound represented by the following general formula (1): (the numerals and signs in the general formula (1) are as described in the description).

Abstract: The present disclosure provides a multi-base material adaptivity pulling removal type binder product, a binder composition and an assembly. The binder product contains an acrylic acid copolymer, a flexibilizer, tackifying resin and an isocyanate curing agent. The binder product comprises a binder layer formed by curing at least a part of the binder composition. The assembly is formed by bonding the binder layer. The binder can be used for firmly bonding various base materials, comprising both high surface energy base materials and low surface energy base materials; meanwhile, the binder can be pulled and removed from the base materials at a large angle. The binder is particularly suitable for the fields of smartphones, tablet computers and a newly developing electronic market.

Abstract: It is an object of the present invention to provide a thermosetting resin composition using a transesterification reaction as a curing reaction, which has a good curability and can be used in various applications. A thermosetting resin composition comprising a polymer (A) composed of a monomer having a (meth)acrylic acid tertiary alkyl ester and a monomer having a hydroxyl group as a structural unit, and a transesterification catalyst (B) as an essential component, and being organic solvent-type or water-borne, wherein the polymer (A) has a glass transition temperature of 80° C. or lower.

Abstract: The invention is a method for producing a copolymer having a repeating unit derived from a conjugated diene-based monomer and using a radical polymerization initiator and a radical generator, wherein the radical polymerization initiator is a compound represented by specific formula (1), and a method for producing a latex in which a copolymer particle is dispersed in water, wherein the copolymer having the repeating unit derived from the conjugated diene-based monomer is synthesized by the method for producing the copolymer. Aspects of the invention provide a method for producing a copolymer in which by-products by Diels-Alder reaction are not readily generated in a copolymerization reaction between a conjugated diene-based monomer and a radically polymerizable monomer other than conjugated diene-based monomers, and a method for producing a latex using this method.

Abstract: The present invention relates to a polymer latex for dip-molding applications obtainable by free-radical emulsion polymerization of a mixture of ethylenically unsaturated monomers comprising at least one conjugated diene and at least one ethylenically unsaturated nitrile compound in an aqueous medium in presence of seed latex particles having a glass transition temperature (mid point temperature Tmg) measured by DSC according to ASTM D3418-03 of ?50° C. to 50° C. wherein the seed latex particles do not contain structural units derived from ethylenically unsaturated nitrile compounds, to a method of preparing said polymer latex, to articles made by using said polymer latex and to a method for preparing dip-molded articles from said polymer latex.

Abstract: Crosslinked polymers made up of polymerized units of cyclic diaminoalkane, aldehyde and bisphenol-S or melamine. A method for removing heavy metals, such as Pb(II) from an aqueous solution or an industrial wastewater sample with these crosslinked polymers is introduced. A process of synthesizing the crosslinked polymers is also described.

Abstract: The invention provides a process for production of polyurethane systems by reacting at least one polyol component with at least one isocyanate component in the presence of one or more catalysts for the isocyanate-polyol and/or isocyanate-water reactions and/or the trimerization of isocyanate, wherein said reacting is carried out in the presence of carrier material and polyamine P.

Abstract: The embodiments described herein generally relate to methods and chemical compositions of triazine-arylhydroxy-aldehyde condensates. In one embodiment, a triazine-arylhydroxy-aldehyde condensate is reacted with at alkoxylation agent to form alkoxylated triazine-arylhydroxy-aldehyde condensates.

Abstract: Energetic nitrogen-rich monomers represented by the general Formula I: wherein each of X1 and X2 is independently NR or a covalent bond, R is H or C1-4 alkyl, each of T1 and T2 is independently a moiety selected from the group consisting of a triazole moiety, a tetrazole moiety and a guanidine moiety, at least one of T1 and T2 being substituted by at least one polymerizable group, are disclosed herein, as well as polymers based thereon, and uses of such polymers.

Abstract: A curable resin composition comprising: (1) a urethane (meth)acrylate comprising a) urethane (meth)acrylate oligomers with a number average molecular weight in the range of from 400 to 1500; and b) urethane (meth)acrylate oligomers with a number average molecular weight in the range of from 1500 to 10000, present in a weight ratio of from 0.1:1 to 25:1; (2) a reactive diluent; and (3) a free radical-generating catalyst, is disclosed.

Abstract: A process comprising, consisting of, or consisting essentially of: foaming a reaction mixture containing at least one polyisocyanate and an isocyanate-reactive compound comprising at least one alkoxylated triazine-arylhydroxy-aldehyde condensate composition wherein the alkoxylated triazine-arylhydroxy-aldehyde condensate composition is a reaction product of a triazine-arylhydroxy-aldehyde condensate and at least one alkylene carbonate, is disclosed.

Abstract: The present invention relates to polymers having dynamic urea bonds and more specifically to polymers having hindered urea bonds (HUBs) with fast hydrolytic kinetics. These urea bonds are aryl-substituted, i.e. aromatic-substituted hindered urea bonds, that demonstrate pH independent hydrolytic kinetics, such that they consistently and rapidly hydrolyze in water from pH 2 to 11. The urea bond dissociation for these materials is generally such that k?1>h?1, which is two orders of magnitudes faster than for aliphatic hindered ureas. The present invention also relates to hydrolytically reversible or degradable linear, branched or network polymers incorporating these HUBs and to precursors for incorporation of these HUBs into these polymers. The technology can be applied to and integrated into a variety of polymers, such as polyureas, polyurethanes, polyesters, polyamides, polycarbonates, polyamines, and polysaccharides to make linear, branched, and cross-linked polymers.

Abstract: A copolymer includes a repeating unit represented by Formula (I); and a repeating unit represented by Formula (II), in Formula (I), R1 represents a hydrogen atom or an alkyl group having 1 to 20 carbon atoms; R2 represents an alkyl group having 1 to 20 carbon atoms and having at least one fluorine atom as a substituent, or a group including —Si(Ra3)(Ra4)O—; L represents a divalent linking group as defined herein; and Ra3 and Ra4 each independently represent an alkyl group as defined herein, in Formula (II), R10 represents a hydrogen atom or an alkyl group having 1 to 20 carbon atoms; R11 and R12 each independently represent a hydrogen atom, a substituted or unsubstituted aliphatic hydrocarbon group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group; R11 and R12 may be linked to each other; and X1 represents a divalent linking group.

Abstract: The present disclosure relates to a method for preparing polybutylene terephthalate, and the method for preparing polybutylene terephthalate of the present disclosure recycles the recovered 1,4-butanediol, so the condensation efficiency in the condenser is not lowered. Therefore, the degree of vacuum of the polycondensation reactor is maintained, so that the preparation efficiency and the degree of polymerization of polybutylene terephthalate can be increased.

Abstract: Provided is a high molecular weight aromatic polycarbonate resin manufacturing method that suppresses the occurrence of heterogeneous structures and can achieve a sufficiently high molecular weight. A high molecular weight aromatic polycarbonate resin manufacturing method including: a step in which a dialcohol compound expressed by general formula (1) and a catalyst are mixed to obtain a catalyst composition; a step in which the obtained catalyst composition is transferred to a prepolymer mixing tank via a transfer pipe, with a transfer period of 10 hours or less; a step in which the transferred catalyst composition and an aromatic polycarbonate prepolymer are mixed in the prepolymer mixing tank to obtain a prepolymer mixture; and a high molecular weight achievement step in which the obtained prepolymer mixture is heat-treated under reduced pressure conditions to obtain a high molecular weight aromatic polycarbonate resin.

Abstract: A polypeptide copolymer, a preparation method thereof, a porous fibrous scaffold including the same, and a method for nerve regeneration or growth are disclosed. The polypeptide copolymer comprises: a glutamate unit; and a glutamic acid unit, wherein a ratio of a content of the glutamic acid unit to a content of the glutamate unit is in a range from 10:90 to 90:10.

Abstract: The present invention relates to polyalkylene imine based polymers, which have aliphatic polyester groups attached to the polyalkylenimine backbone via an carboxamide group. The novel polymers are particularly useful as dispersants for pigments, in particular as dispersants for pigments in non-aqueous compositions. The polyalkylene imine based polymers are characterized by having a) a polyalkylene imine backbone; b) at least one aromatic moiety P.1, which is bound to a nitrogen atom of the polyalkylene imine backbone via an carboxamide or carboximide group; and c) at least one aliphatic polyester moiety P.2, which is bound to a nitrogen atom of the polyalkylene imine backbone via an carboxamide group.

Abstract: A curable composition can have a surface with amphiphilic properties which is thus able to counteract biofouling. The curable composition includes: a component A: at least one polysiloxane, a component B: at least one polyether bearing silyl groups and/or a reaction product of a polyether bearing silyl groups with one or more isocyanate-containing compounds, and a component C: at least one catalyst.